The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus

Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,468

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,193

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,125

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Matulonis, U. A., Shapira‐Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I. B., Raspagliesi, F., Sonke, G. S., Birrer, M. J., Provencher, D. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz135 · Cited by 871

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C. T., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 797

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01638 · Cited by 736

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J., Grischke, E., Furlanetto, J., Tesch, H., Hanusch, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 698

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Kim, Y. H., Bagot, M., Pinter‐Brown, L. C., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S. J., TOKURA, Y., Vermeer, M. H., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 679

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

Hwang, W., Adams, S. F., Tahirović, E., Hagemann, I. S., & Coukos, G. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 674

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A. C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 642

Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial

Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

Lutz, E. R., Wu, A. A., Bigelow, E. O., Sharma, R. B., Mo, G., Soares, K. C., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 560

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Lipson, E. J., Sharfman, W. H., Drake, C. G., WOLLNER, I. S., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 551

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Domchek, S. M., Postel-Vinay, S. C., Im, S., Park, Y. H., Delord, J., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 496

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Disis, M. L., Taylor, M. H., Kelly, K. L., Beck, J. T., Gordon, M. S., Moore, K. M., Patel, M. R., Chaves, J. M., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 448

Layer-by-layer biofunctionalization of nanostructured porous silicon for high-sensitivity and high-selectivity label-free affinity biosensing

Mariani, S., Robbiano, V., Strambini, L. M., Debrassi, A., Egri, G., Dähne, L., & Barillaro, G. (2018) · Nature Communications · doi:10.1038/s41467-018-07723-8 · Cited by 409

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406

Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy

Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Rugo, H. S., Delord, J., Im, S., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J. C., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3452 · Cited by 381

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J. N., Alumkal, J. J., Drake, C. G., THOMAS, G. V., Redmond, W. L., Farhad, M. E., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 366

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Färkkilä, A., Gulhan, D., Casado, J., Jacobson, C. A., Nguyen, H. Q., Kochupurakkal, B. S., Maliga, Z., Yapp, C., Chen, Y., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 302

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

O’Neil, B. H., Wallmark, J. M., Lorente, D., Élez, E., Raimbourg, J., Gomez‐Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Razak, A. R. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189848 · Cited by 299

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Jung, K. H., LoRusso, P. M., Burris, H. A., Gordon, M. S., Bang, Y., Hellmann, M. D., Cervantes, A. M. R., de Olza, M. O., Marabelle, A., Hodi, F. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2740 · Cited by 281

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Dérangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 280

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 274

Steps in metastasis: an updated review

Majidpoor, J., & Mortezaee, K. (2021) · Medical Oncology · doi:10.1007/s12032-020-01447-w · Cited by 266

The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

Lu, C., Redd, P. S., Lee, J. R., Savage, N. M., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 242

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233

Enhancing global access to cancer medicines

Cortés, J., Pérez-García, J. M., Llombart‐Cussac, A., Curigliano, G., Saghir, N. S. E., Cardoso, F., Barrios, C. H., Wagle, S. M. S., Roman, J., Harbeck, N., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21597 · Cited by 213

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Rodrigues, D. N., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B. K., Seed, G., Mateo, J., Riisnaes, R., Mullane, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 209

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Mahalingam, D., Wilkinson, G., Eng, K. H., Fields, P., Raber, P. L., Moseley, J. L., Cheetham, K., Coffey, M. C., Nuovo, G. J., Kaliński, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2078 · Cited by 193

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Liu, S., Qin, T., Liu, Z., Wang, J., Jia, Y., Feng, Y., Gao, Y., & Li, K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2511-3 · Cited by 192

CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis

Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117534 · Cited by 180

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Terranova-Barberio, M., Pawłowska, N., Dhawan, M., Moasser, M. M., Chien, A. J., Melisko, M., Rugo, H. S., Rahimi, R., Deal, T. R., DAUD, A. I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17414-y · Cited by 180

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174

The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis

Orhan, A., Vogelsang, R. P., Andersen, M. B., Madsen, M. T., Hölmich, E. R., Raskov, H., & Gögenür, I. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.013 · Cited by 170

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Middleton, G., Brock, K., Savage, J. S., Mant, R., Summers, Y., Conibear, J., Shah, R. N. H., Ottensmeier, C. H. H., Shaw, P. H., Lee, S. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30033-3 · Cited by 168

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming

Mishra, R., Haldar, S., Placencio, V. R., Madhav, A., Rohena-Rivera, K., Agarwal, P., Duong, F. L., Angara, B., Tripathi, M., Liu, Z., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99397 · Cited by 167

PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients

Concha‐Benavente, F., Kansy, B., Moskovitz, J. M., Moy, J. D., Chandran, U. R., & Ferris, R. L. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0062 · Cited by 162

Immune escape: A critical hallmark in solid tumors

Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118110 · Cited by 162

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer

Haffner, M. C., Güner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H. K., Esopi, D., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.02.014 · Cited by 160

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 155

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Zhang, Q., & Liu, F. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2696-5 · Cited by 142

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

Liu, J. F., Gordon, M. S., Veneris, J. T., Braiteh, F., Balmanoukian, A. S., Eder, J. P., Oaknin, A., Hamilton, E. P., Wang, Y., Sarkar, I., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.021 · Cited by 138

NSD2 is a conserved driver of metastatic prostate cancer progression

Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 122

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

Li, Y., He, M., Zhou, Y., Yang, C., Wei, S., Bian, X., Christopher, O., & Xie, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00139 · Cited by 119

Super-geometric electron focusing on the hexagonal Fermi surface of PdCoO2

Bachmann, M. D., Sharpe, A. L., Barnard, A., Putzke, C. M., Koenig, M., Khim, S., Goldhaber‐Gordon, D., Mackenzie, A. P., & Moll, P. J. W. (2019) · RePEc: Research Papers in Economics · Cited by 116

Extreme rainfall events alter the trophic structure in bromeliad tanks across the Neotropics

Romero, G. Q., Marino, N. A. C., MacDonald, A. A. M., Céréghino, R., Trzcinski, M. K., Acosta-Mercado, D., Leroy, C., Corbara, B., Farjalla, V. F., Barberis, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17036-4 · Cited by 116

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 115

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Pernot, S., Terme, M., Radosevic‐Robin, N., Castan, F., Badoual, C., Marcheteau, E., Penault-Llorca, F. M., Bouché, O., Bennouna, J., François, É., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00983-3 · Cited by 114

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112

Cancer‐associated fibroblasts: Secretions, interactions, and therapy

Farhood, B., Najafi, M., & Mortezaee, K. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27703 · Cited by 109

The Landscape of Immune Cells Infiltrating in Prostate Cancer

Wu, Z., Chen, H., Luo, W., Zhang, H., Li, G., Zeng, F., & Deng, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.517637 · Cited by 109

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., RADEMAKER, A. W., Nelson, V. M., Tsarwhas, D., Cristofanilli, M., & Gradishar, W. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000173 · Cited by 108

Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives

Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 107

Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance

Najafi, M., Mortezaee, K., & Ahadi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.076 · Cited by 95

Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer

Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22708 · Cited by 92

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 80

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer

Foulds, G. A., Vadakekolathu, J. N., Abdel-Fatah, T. M. A., Nagarajan, D., Reeder, S., Johnson, C., Hood, S. P., Moseley, P. M., Chan, S. Y. T., Pockley, A. G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02028 · Cited by 77

Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design

Pujade-Lauraine, É., Fujiwara, K., Dychter, S. S., Devgan, G., & Monk, B. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0070 · Cited by 76

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

Bassani‐Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C. L., Stevenson, B. J., Thierry, A., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 75

Stromal reprogramming: A target for tumor therapy

Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117049 · Cited by 74

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies

Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13343 · Cited by 71

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70

Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α

Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 63

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis

Yang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 61

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Redman, J. M., Steinberg, S. M., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0409-8 · Cited by 60

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial

Weed, D. T., Zilio, S., dos Reis, I. M., Sargi, Z., Abouyared, M., Gomez-Fernandez, C. R., Civantos, F., Rodriguez, C. P., & Serafini, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01206 · Cited by 60

Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma

Li, L., Li, W., Wang, C., Xu, Y., Wang, Y., Niu, C. S., Zhang, X., Li, M., Tian, H., Cheng, Y., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.009 · Cited by 60

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer

Ross, A. E., Hurley, P. J., Tran, P. T., Rowe, S. P., Benzon, B., Neal, T. O., Chapman, C. G., Harb, R., Milman, Y., Trock, B. J., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0176-8 · Cited by 56

Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study

Wang, L. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0512-6 · Cited by 50

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Zhao, G. Q., Rangwala, R. A., & Matei, D. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5513 · Cited by 49

Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

Sampedro-Núñez, M., Serrano-Somavilla, A., Adrados, M., Cameselle-Teijeiro, J. M., Blanco-Carrera, C., Cabezas-Agricola, J. M., Martínez-Hernández, R., Martín-Pérez, E., Muñoz de Nova, J. L., Díaz, J. Á., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36129-1 · Cited by 49

Redox tolerance and metabolic reprogramming in solid tumors

Mortezaee, K. (2020) · Cell Biology International · doi:10.1002/cbin.11506 · Cited by 48

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 47

Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer

Liang, S., Niu, L., Xu, K., Wang, X., Liang, Y., Zhang, M., Chen, J., & Lin, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.10.003 · Cited by 42

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

Nishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., et al. (2020) · Cancer Science · doi:10.1111/cas.14340 · Cited by 40

Interval breast cancer is associated with other types of tumors

Graßmann, F., He, W., Eriksson, M., Gabrielson, M., Hall, P. N., & Czene, K. (2019) · Nature Communications · doi:10.1038/s41467-019-12652-1 · Cited by 37

Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Shindo, Y., Hazama, S., Suzuki, N., Iguchi, H., Uesugi, K., Tanaka, H., Aruga, A., Hatori, T., Ishizaki, H., Umeda, Y., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0509-1 · Cited by 36

Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer

Perrot‐Applanat, M., Vacher, S., Pimpie, C., Chemlali, W., Derieux, S., Pocard, M. D., & Bièche, I. (2019) · Oncology Letters · doi:10.3892/ol.2019.10392 · Cited by 35

Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma

Malchiodi, Z. X., & Weiner, L. M. (2021) · Cancers · doi:10.3390/cancers13030405 · Cited by 34

Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma

Lee, H. S., Leem, G., Kang, H., Jo, J. H., Chung, M. J., Jang, S. J., Yoon, D. H., Park, J. Y., Park, S. W., Song, S. Y., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15265 · Cited by 34

Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow

Buschhaus, J. M., Humphries, B. A., Eckley, S. S., Robison, T. H., Cutter, A. C., Rajendran, S., Haley, H. R., Bevoor, A. S., Luker, K. E., & Luker, G. D. (2020) · Oncogene · doi:10.1038/s41388-020-01391-z · Cited by 33

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)

Evert, J. S. H., Bekkers, R. L. M., Ottevanger, N. P. B., Schaap, N. P., Hobo, W. A., Jansen, J. H., Massuger, L. F. A. G., & Dolstra, H. (2019) · Medicine · doi:10.1097/md.0000000000014290 · Cited by 30

Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma

Huang, L., Deng, X., Chang, F., Wu, X., Wu, Y., & Diao, Q. (2018) · Medicine · doi:10.1097/md.0000000000012858 · Cited by 28

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis

Guo, X., Li, W., Hu, J., Zhu, E. C., & Su, Q. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02903-2 · Cited by 28

CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration

Nguyen, K. T. P., Druhan, L. J., Avalos, B. R., Zhai, L., Rauova, L., Nesmelova, I. V., & Dréau, D. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109488 · Cited by 25

The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review

Zhu, X., & Lang, J. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.002 · Cited by 23

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Lee, J., Kim, J., Lim, M. C., Kim, S., Kim, H. S., Choi, C. H., Yi, J. Y., Park, S., Kim, B., & on behalf of KGOG investigators (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e112 · Cited by 23

Laparoscopic Surgery Versus Open Surgery for Colorectal Cancer: Impacts on Natural Killer Cells

Shi, L., Guo, H., Zheng, Z., Liu, J., Jiang, Y., & Su, Y. (2020) · Cancer Control · doi:10.1177/1073274820906811 · Cited by 19

The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer

Shams, K., Larypoor, M., & Salimian, J. (2021) · Medical Oncology · doi:10.1007/s12032-021-01591-x · Cited by 18

Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies

Strauss, J., Gatti-Mays, M. E., Cho, B., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Lamping, E., Burmeister, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct075 · Cited by 16

Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma

Karakhanova, S., Mosl, B., Harig, S., von Ahn, K., Fritz, J., Schmidt, J., Jäger, D., Werner, J., & Bazhin, A. V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034104 · Cited by 16

Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

Nakashima, J., Imaizumi, Y., Taniguchi, H., Ando, K., Iwanaga, M., Itonaga, H., Sato, S., Sawayama, Y., Hata, T., Yoshida, S., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2509-0 · Cited by 15

The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

Tian, Y., Zhang, Z., Yang, X., Li, D., Zhang, L., Li, Z., Zhang, S., Mao, Y., Jin, C., & Zhao, Y. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00261 · Cited by 12

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

Maughan, B. L., Pal, S. K., Gill, D. M., Boucher, K. M., Martin, C., Salgia, M. M., Nussenzveig, R. H., Liu, T., Hawks, J., Batten, J. A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0652 · Cited by 12

Extracellular vesicles as tools and targets in therapy for diseases

Kumar, M. A., Baba, S. K., Sadida, H. Q., Al-Marzooqi, S. K., Jerobin, J., Altemani, F. H., Algehainy, N. A., Alanazi, M. A., Abou‐Samra, A., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,545

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,486

Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments

Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 268

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Marei, H. E. S., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02902-0 · Cited by 269

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 135

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 46

PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters

Stanowska, O., Kuczkiewicz‐Siemion, O., Dębowska, M., Olszewski, W. P., Jagiełło-Gruszfeld, A., Tysarowski, A., & Prochorec‐Sobieszek, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195524 · Cited by 22

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 84

PD-1/PD-L1 axis importance and tumor microenvironment immune cells

Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 52